Zynex Reaffirms 2024 Revenue Guidance Of At Least $227M
$ZYXI
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Health Care
Zynex Reaffirms 2024 Revenue Guidance Of At Least $227M
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/16/2023 | $13.00 | Outperform | RBC Capital Mkts |
| 1/6/2023 | $10.00 → $18.00 | Neutral → Overweight | Piper Sandler |
| 2/28/2022 | $15.50 → $10.00 | Buy | B. Riley Securities |
| 2/25/2022 | $22.00 → $20.00 | Buy | HC Wainwright & Co. |
| 7/30/2021 | $25.00 → $22.00 | Buy | HC Wainwright & Co. |
| 7/16/2021 | $19.50 | Neutral → Buy | B. Riley Securities |
ENGLEWOOD, Colo., Oct. 24, 2024 /PRNewswire/ -- Zynex, Inc. (NASDAQ:ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today reported its financial and operational results for the third quarter ended September 30, 2024. Key Third Quarter Highlights and Business Update Q3 2024 orders increased 13% year-over-year.Q3 2024 net revenue of $50.0 million.Q3 2024 net income of $2.4 million; Diluted EPS $0.07.Q3 2024 cash flow from operations of $7.1 millio
ENGLEWOOD, Colo., Oct. 16, 2024 /PRNewswire/ -- Zynex, Inc. (NASDAQ:ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, will hold a conference call on Thursday, October 24, 2024 at 4:15 PM Eastern Time to discuss its financial results for the third quarter ended September 30, 2024. Financial results will be issued in a press release prior to the call. Zynex management will host the conference call, followed by a question and answer session. Date: T
ENGLEWOOD, Colo., Sept. 4, 2024 /PRNewswire/ -- Zynex, Inc. (NASDAQ:ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, announced it will present at the upcoming HC Wainwright Global Investment Conference, which is being held September 9-11, 2024. Zynex's fireside chat will be held in person and webcast live on September 10 at 11:30 AM ET at the Lotte New York Palace Hotel in New York, NY. You can listen to the webcast at Webcast Link. Dan Moorhead,
RBC Capital Mkts initiated coverage of Zynex with a rating of Outperform and set a new price target of $13.00
Piper Sandler upgraded Zynex from Neutral to Overweight and set a new price target of $18.00 from $10.00 previously
B. Riley Securities reiterated coverage of Zynex with a rating of Buy and set a new price target of $10.00 from $15.50 previously
SC 13D/A - ZYNEX INC (0000846475) (Subject)
RBC Capital analyst Shagun Singh reiterates Zynex (NASDAQ:ZYXI) with a Outperform and maintains $15 price target.
HC Wainwright & Co. analyst Yi Chen reiterates Zynex (NASDAQ:ZYXI) with a Buy and maintains $21 price target.
10-Q - ZYNEX INC (0000846475) (Filer)
8-K - ZYNEX INC (0000846475) (Filer)
10-Q - ZYNEX INC (0000846475) (Filer)
ENGLEWOOD, Colo., Oct. 24, 2024 /PRNewswire/ -- Zynex, Inc. (NASDAQ:ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today reported its financial and operational results for the third quarter ended September 30, 2024. Key Third Quarter Highlights and Business Update Q3 2024 orders increased 13% year-over-year.Q3 2024 net revenue of $50.0 million.Q3 2024 net income of $2.4 million; Diluted EPS $0.07.Q3 2024 cash flow from operations of $7.1 millio
ENGLEWOOD, Colo., Oct. 16, 2024 /PRNewswire/ -- Zynex, Inc. (NASDAQ:ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, will hold a conference call on Thursday, October 24, 2024 at 4:15 PM Eastern Time to discuss its financial results for the third quarter ended September 30, 2024. Financial results will be issued in a press release prior to the call. Zynex management will host the conference call, followed by a question and answer session. Date: T
Q2 2024 Revenue Increased 11% to $49.9 Million ENGLEWOOD, Colo., July 25, 2024 /PRNewswire/ -- Zynex, Inc. (NASDAQ:ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today reported its financial and operational results for the second quarter ended June 30, 2024. Key Second Quarter Highlights and Business Update Q2 2024 orders increased 20% year-over-year, the highest number of orders in Company history for the ninth consecutive quarter.Q2 2024 reve
ENGLEWOOD, Colo., June 13, 2022 /PRNewswire/ -- Zynex, Inc. ("Zynex or the "Company) (NASDAQ:ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today announced that it has changed its auditors from Plante & Moran, PLLC ("Plante Moran") as the Company's independent registered accounting firm to Marcum LLP effective June 13, 2022. The appointment of Marcum LLP was made after careful consideration and an evaluation process by the Company and approved by the Board of Directors and the Audit Committee of the Company.
ENGLEWOOD, Colo., April 20, 2021 /PRNewswire/ -- Zynex, Inc. (NASDAQ:ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, stroke rehabilitation, cardiac monitoring and neurological diagnostics today announced that it has hired Donald Gregg as the Vice President of Sales and Operations of its Monitoring Solutions Division. In this position, Donald will lead operations, sales, marketing and product development of the Monitoring Solution Division including the production and launch of the CM-1500 Blood Volume Monitor which was granted 510(k) clearance by the U.S. Food and Drug Administration in 2020.
ENGLEWOOD, Colo., Jan. 28, 2021 /PRNewswire/ -- Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, stroke rehabilitation, cardiac monitoring and neurological diagnostics today announced that it has promoted Anna Lucsok to Chief Operating Officer (COO) of Zynex Medical, its pain management division. Joseph Papandrea previously held the position of COO. Thomas Sandgaard, founder and CEO said: "I would personally like to thank Joseph for his leadership and contributions. We wish him nothing but the best in the future. I would also like to congratulate Anna on a well-deserved prom
4 - ZYNEX INC (0000846475) (Issuer)
4 - ZYNEX INC (0000846475) (Issuer)
4 - ZYNEX INC (0000846475) (Issuer)